search
Back to results

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BI 10773 Placebo
BI 10773
BI 10773 Placebo
BI 10773
BI 10773 Placebo
BI 10773 Placebo
BI 10773
BI 10773
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Male and postmenopausal or hysterectomised female patients with proven diagnosis of type 2 diabetes mellitus treated with diet and exercise only or on a maximum of two oral antidiabetic agents except thiazolidindiones with at least one agent taken at 50% of its maximum dose or less.
  2. Glycosylated haemoglobin A1 (HbA1c) £ 8.5 % at screening.
  3. Age >21 and Age <70 years (male and hysterectomised female patients) Age >60 and Age <70 years (postmenopausal female patients)
  4. Body Mass Index (BMI) >18.5 and <40 kg/m2
  5. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation

Exclusion criteria:

  1. Antidiabetic treatment with insulin or glitazones or with more than one oral hypoglycaemic agent (except if 2 agents and at least one of them not taken at more than 50% of its maximum dose)
  2. Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) on two consecutive days during washout.
  3. Glycosylated haemoglobin A1 (HbA1c) >8.5% at screening
  4. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension, such as:

    • Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative disorders, diabetic foot)
    • Renal insufficiency (calculated creatinine clearance < 80 ml/min/1.73m²)
    • Cardiac insufficiency NYHA II-IV, myocardial infarction, other known cardiovascular diseases including hypertension > 160/95mmHg (measured at training visit and each of the timepoints of Day -1), stroke and TIA (Transistoric ischaemic attack)
    • Neurological disorders (such as epilepsy) or psychiatric disorders
    • Acute or relevant chronic infections (e.g. HIV, repeated urogenital infections)
    • Any gastrointestinal, hepatic, respiratory, endocrine or immunological disorder
  5. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  6. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  7. A history of additional risk factors for TdP (torsade des pointes) (e.g., heart failure, hypokalemia, family history of sudden death before the age of 50)

Sites / Locations

  • 1245.2.1 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

BI 10773 (dose group 3)

BI 10773 (dose group 4)

BI 10773 (dose group 1)

BI 10773 (dose group 2)

Arm Description

multiple doses as tablet

multiple doses as tablet

multiple doses as tablet

multiple doses as tablet

Outcomes

Primary Outcome Measures

Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).
Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results
Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results
Micturition Frequency
Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.
Assessment of Tolerability by Investigator
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.

Secondary Outcome Measures

Concentration of the Analyte in Plasma
Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)
AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.
Time to Maximum Concentration of the Analyte in Plasma
Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state
Terminal Rate Constant in Plasma
Terminal rate constant in plasma after first dose and at steady-state
Half-life and Mean Residence Time of the Analyte in Plasma
Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.
Apparent Volume of Distribution During the Terminal Phase
Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).
Amount of Analyte Eliminated in Urine
Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)
Fraction of Analyte Excreted Unchanged in Urine
Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.
Apparent and Renal Clearance of the Analyte in Plasma
Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.
Peak Trough Fluctuation
Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state
Linearity Index
The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.
Accumulation Ratios
Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau
Change From Baseline to Day 8 in Urinary Glucose Excretion
Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.
Mean Daily Glucose
Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.
Fasting Plasma Glucose
Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.
Serum Insulin
Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.
Serum Insulin
Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) & Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)

Full Information

First Posted
August 9, 2013
Last Updated
July 3, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01924767
Brief Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
Official Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing, including dose proportionality and assessment of steady state.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BI 10773 (dose group 3)
Arm Type
Experimental
Arm Description
multiple doses as tablet
Arm Title
BI 10773 (dose group 4)
Arm Type
Experimental
Arm Description
multiple doses as tablet
Arm Title
BI 10773 (dose group 1)
Arm Type
Experimental
Arm Description
multiple doses as tablet
Arm Title
BI 10773 (dose group 2)
Arm Type
Experimental
Arm Description
multiple doses as tablet
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773 Placebo
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
po taken fasting with 240 mL water
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
po taken fasting with 240 mL water
Primary Outcome Measure Information:
Title
Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
Description
Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).
Time Frame
day 1 to day 21
Title
Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results
Description
Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results
Time Frame
day 1 to day 21
Title
Micturition Frequency
Description
Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.
Time Frame
Baseline and Day 9
Title
Assessment of Tolerability by Investigator
Description
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.
Time Frame
day 21
Secondary Outcome Measure Information:
Title
Concentration of the Analyte in Plasma
Description
Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)
Description
AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Time to Maximum Concentration of the Analyte in Plasma
Description
Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Terminal Rate Constant in Plasma
Description
Terminal rate constant in plasma after first dose and at steady-state
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Half-life and Mean Residence Time of the Analyte in Plasma
Description
Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Apparent Volume of Distribution During the Terminal Phase
Description
Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Amount of Analyte Eliminated in Urine
Description
Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)
Time Frame
0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Title
Fraction of Analyte Excreted Unchanged in Urine
Description
Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.
Time Frame
0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Title
Apparent and Renal Clearance of the Analyte in Plasma
Description
Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Peak Trough Fluctuation
Description
Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Linearity Index
Description
The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Accumulation Ratios
Description
Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau
Time Frame
-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Title
Change From Baseline to Day 8 in Urinary Glucose Excretion
Description
Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.
Time Frame
-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8
Title
Mean Daily Glucose
Description
Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.
Time Frame
0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8
Title
Fasting Plasma Glucose
Description
Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.
Time Frame
-0:30 (Pre dose samples)
Title
Serum Insulin
Description
Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.
Time Frame
0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8
Title
Serum Insulin
Description
Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) & Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)
Time Frame
0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Male and postmenopausal or hysterectomised female patients with proven diagnosis of type 2 diabetes mellitus treated with diet and exercise only or on a maximum of two oral antidiabetic agents except thiazolidindiones with at least one agent taken at 50% of its maximum dose or less. Glycosylated haemoglobin A1 (HbA1c) £ 8.5 % at screening. Age >21 and Age <70 years (male and hysterectomised female patients) Age >60 and Age <70 years (postmenopausal female patients) Body Mass Index (BMI) >18.5 and <40 kg/m2 Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation Exclusion criteria: Antidiabetic treatment with insulin or glitazones or with more than one oral hypoglycaemic agent (except if 2 agents and at least one of them not taken at more than 50% of its maximum dose) Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) on two consecutive days during washout. Glycosylated haemoglobin A1 (HbA1c) >8.5% at screening Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension, such as: Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative disorders, diabetic foot) Renal insufficiency (calculated creatinine clearance < 80 ml/min/1.73m²) Cardiac insufficiency NYHA II-IV, myocardial infarction, other known cardiovascular diseases including hypertension > 160/95mmHg (measured at training visit and each of the timepoints of Day -1), stroke and TIA (Transistoric ischaemic attack) Neurological disorders (such as epilepsy) or psychiatric disorders Acute or relevant chronic infections (e.g. HIV, repeated urogenital infections) Any gastrointestinal, hepatic, respiratory, endocrine or immunological disorder History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms) A history of additional risk factors for TdP (torsade des pointes) (e.g., heart failure, hypokalemia, family history of sudden death before the age of 50)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1245.2.1 Boehringer Ingelheim Investigational Site
City
Neuss
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.2_U09-1271-01.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.2_Literature.pdf
Description
Related Info

Learn more about this trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

We'll reach out to this number within 24 hrs